AstraZeneca is working with the Biomedical Advanced Research and Development Authority (BARDA) to assist in the effort to maximize and accelerate US production of COVID-19 vaccines. As part of that effort, and in full cooperation with the US Government, AstraZeneca will relocate production of AZD1222 vaccine drug substance from the Emergent facility in Baltimore, Maryland. The company will work with the US Government to identify an alternative location for domestic drug substance production of AZD1222.
AstraZeneca and the US Government continue to work closely together to support agreed upon plans for the development, production and full delivery of the vaccine. AstraZeneca is currently progressing submission to the Food and Drug Administration (FDA) for Emergency Use Authorization of AZD1222.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory & Immunology. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca-us.com and follow us on Twitter @AstraZenecaUS.
US Media Line
|+1 302 885 2677|